Cipher Pharmaceuticals (TSE:CPH – Get Rating) (NASDAQ:CPHR) will be issuing its quarterly earnings data after the market closes on Thursday, May 11th.
Cipher Pharmaceuticals Trading Up 2.4 %
Shares of CPH opened at C$3.36 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.67 and a current ratio of 4.07. The stock has a 50-day moving average price of C$3.48 and a 200 day moving average price of C$3.54. Cipher Pharmaceuticals has a one year low of C$2.00 and a one year high of C$4.07. The company has a market capitalization of C$84.27 million, a P/E ratio of 2.38 and a beta of 1.05.
Analysts Set New Price Targets
Separately, Leede Jones Gab reiterated a “buy” rating on shares of Cipher Pharmaceuticals in a research report on Friday, March 17th.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug.
- Is the Electric Vehicle Movement Losing Steam?
- 3 High-Yield Banks Insiders Are Buying
- Will ChatGPT Be the Final Nail in the Coffin for Chegg?
- Is the Market Reacting Too Negatively to Pinterest Earnings?
- More Analysts Should See Energizer Holdings As A Buy: Here Is Why
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.